Antibacterial Therapies Drug Development Pipeline Review, 2017 - The Market Report
The antibacterial drug market covers the drugs used in the prophylaxis
and treatment of bacterial infections. With a growing global concern over
antimicrobial resistance and its progressive growth, there is a pronounced need
for innovation within this market.
There are over 1400 products in active development in the antibacterial
drug market, with the majority of products being small molecules. Vaccines are
also well established within the market, and accounts for approximately 25% of
the pipeline.
Currently, drugs for the prevention of bacterial infections are typically
vaccines which help to train the body’s immune system to fight off bacterial
infections caused by specific bacterial strains. However, several prophylactic
monoclonal antibodies are now in the pipeline and may impact the market in the
near future.
Drugs for the treatment of bacterial infections are slightly more varied.
Most common are beta-lactam antibiotics, such as penicillin, and protein
synthesis inhibitors. However, bacterial resistance has reduced the efficacy of
many of these drugs. As a result the pipeline includes a variety of
new-generation protein synthesis inhibitors and beta-lactam/beta-lactamase inhibitor
combination drugs, which are active against currently hard to treat bacterial
strains.
The report provides comprehensive information on the pipeline development
landscape for Pneumonia, Methicillin-resistant staphylococcus aureus (MRSA) and
Tuberculosis, from Discovery through to the Pre-Registration stage. This
includes an analysis of products by stage of development, molecular target,
mechanism of action (MoA), route of administration (RoA) and molecule type. A
list of all products in development is provided, including dormant and
discontinued projects. Finally, the report provides an overview of key players
involved in the development of products in this area, and outlines recent
updates and press releases in the field.
What is
the scope of the report ?
- Which companies are the most active within the pipeline for
antibacterial drugs?
- Which pharmaceutical approaches are the most prominent at each stage of
the pipeline and within each indication?
- To what extent do universities and institutions play a role within this
pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to
have happened in this disease area?
Table of
Content
Introduction
GBI Research Report Coverage
Tuberculosis Overview
Pneumonia
Methicillin-Resistant Staphylococcus aureus (MRSA)
Therapeutics Development
Tuberculosis
About
Aarkstore
Aarkstore Enterprise
is a leading provider of business and financial information and solutions
worldwide. We specialize in providing online market business information on
market research reports, books, magazines, conference at competitive prices,
and strive to provide excellent and innovative service to our customers.
Contact
Details:
Aarkstore
Phone: 91 - 998 729 5242
Comments
Post a Comment